BNTC: financial statements from SEC — TradeAlmanac

BNTC

Benitec Biopharma Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Revenue	0	0	0	—	0	0	0
Research and development	6m	6m	3m	3m	6m	5m	4m
Selling, general and administrative	7m	8m	6m	7m	4m	5m	2m
Operating expenses	14m	13m	10m	10m	10m	11m	6m
Operating income	−14m	−13m	−10m	−10m	−10m	−11m	−6m
Net income	−12m	−12m	−9m	−9m	−9m	−10m	−5m
Earnings per share	−0.24	−0.26	−0.22	−0.21	−0.24	−0.26	−0.18
Earnings per share, diluted	−0.24	−0.26	−0.22	−0.21	−0.24	−0.26	−0.18
Weighted average shares	49m	46m	42m	41m	39m	37m	28m
Weighted average shares, diluted	49m	46m	42m	41m	39m	37m	28m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	185m	189m	94m	98m	104m	78m	68m	51m
Current assets	186m	190m	95m

Cash flow

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Operating cash flow	—	—	−3m	—	—	−5m
Depreciation and amortisation	14,000	14,000	13,000	13,000

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)